Prof. Dr. Ben Barsties v. Latoszek, Graf-Adolf-Straße 67, 40210 Düsseldorf, Tel: +49 211 2807390, E-mail:
J Prev Alzheimers Dis. 2024;11(6):1789-1797. doi: 10.14283/jpad.2024.132.
The potential of biomarkers in the detection of Alzheimer's disease (AD) is prominent. Acoustics may be useful in this context but the evaluation and weighting for specific acoustic parameters on continuous speech is missing. This meta-analysis aimed to explore the significance of acoustic parameters from acoustic speech analysis on continuous speech, as a diagnostic tool for clinical AD.
Applying PRISMA protocol, a comprehensive search was done in MEDLINE, Scopus, Web of Science, and CENTRAL, from 1960 to January 2024. Cross-sectional studies comparing the acoustic speech analysis between AD patients and healthy controls (HC), were taken into account. The bias risk of the included studies were examined via JBI checklist. Using Review Manager v.5.4.1, the mean differences of acoustic speech parameters among AD and HC were weighted, and the pooled analysis and the heterogeneity statistics were conducted.
In total, 1112 records (without duplicates) were obtained, and 11 papers with 7 acoustic parameters were included for this study, and 8 from 11 studies were identified with a low level of bias. Five from 7 acoustic parameters revealed significant differences among the two groups (p-values ≤ 0.01), in which for all rate-related and interruption-related acoustic parameters were the most prominent and less in temporal-related acoustic parameters.
Although a small number of acoustic parameters on continuous speech could be evaluated in the detection of clinical AD, the greatest potential of acoustic biomarkers for AD appeared to exist in two of three categories. Further contributions of high-quality studies are needed to support evidence for acoustics as biomarkers for AD.
生物标志物在阿尔茨海默病（AD）检测中的潜力显著。在这种情况下，声学可能是有用的，但对连续语音中特定声学参数的评估和加权尚不清楚。本荟萃分析旨在探讨连续语音中声学参数在临床 AD 诊断工具中的重要性。
根据 PRISMA 方案，从 1960 年到 2024 年 1 月，对 MEDLINE、Scopus、Web of Science 和 CENTRAL 进行了全面检索。纳入了比较 AD 患者和健康对照组（HC）之间声学语音分析的横断面研究。使用 JBI 清单检查纳入研究的偏倚风险。使用 Review Manager v.5.4.1，对 AD 和 HC 之间声学语音参数的均值差异进行加权，并进行合并分析和异质性统计。
总共获得了 1112 条记录（无重复），纳入了 11 篇论文和 7 个声学参数，其中 8 篇来自 11 项研究被确定为低偏倚水平。7 个声学参数中有 5 个在两组之间存在显著差异（p 值≤0.01），其中所有与速率相关和中断相关的声学参数最为显著，与时间相关的声学参数则较少。
尽管可以评估连续语音中的少数声学参数来检测临床 AD，但声学生物标志物在 AD 中的最大潜力似乎存在于三个类别中的两个类别中。需要高质量研究的进一步贡献来支持声学作为 AD 生物标志物的证据。
